Efficacy and Safety of Imatinib in Chordoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00150072
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : February 23, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

September 7, 2005
September 8, 2005
February 23, 2017
October 2004
April 2008   (Final data collection date for primary outcome measure)
Tumor response [ Time Frame: Every 3 months for 2 years ]
objective response according to RECIST and clinical response
Primary: Overall response rate; patterns of tumor response
Complete list of historical versions of study NCT00150072 on Archive Site
  • Overall survival [ Time Frame: 2 years ]
    from the first day of sudy treatment to the day of death for any cause
  • Progression free survival [ Time Frame: 2 years ]
    from the first day of sudy treatment to the day of death for any cause or documented progression
  • Safety and tolerability [ Time Frame: 2 years ]
    frequency of adverse events, abnormal lab values, bone pain, use of analgesic medication
  • proportion of patients undergoing complete surgery [ Time Frame: 2 years ]
    number of pts undergoing complete surgery vs the one of pts not amenable to complete surgery at enrolment
Secondary: Conversion rate to surgical resectability or non-demolitive surgical respectability; overall survival (OS), Progression-free survival (PFS).
Not Provided
Not Provided
Efficacy and Safety of Imatinib in Chordoma
Phase II Study of Imatinib Mesylate in Chordoma
Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical and pathological response. Aim of the study will be to explore treatment's activity, but also the potential impact of tumor response, the feasibility and outcome of subsequent surgery and radiotherapy. In addition, patterns of tumour response need to be investigated as well, given the peculiar patterns of response shown with molecular-targeted therapy in solid tumors.
Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: imatinib
Experimental: imatinib
Intervention: Drug: imatinib
Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, Rowe JM, Schwarz M, Goldschmidt N, Nagler A. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010 Oct 1;116(19):4564-72. doi: 10.1002/cncr.25351. Erratum in: Cancer. 2011 Jan 1;117(1):230.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
April 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histological diagnosis of chordoma.
  2. Biomolecular or immunohistochemical evidence of Imatinib mesylate target (PDGFRβ activation and/or presence of PDGFB). Biomolecular assessment of PDGFRβ activation should be made whenever possible. To this end, if frozen material is not available, obtaining of, fresh material is encouraged, if it should be obtained with no major distress for the patient, preferably through an incisional biopsy (to allow immunoprecipitation) or, if this is not feasible, a Trucut biopsy (to allow Western Blot assessment). However, if frozen or fresh material cannot be obtained, paraffined material is also acceptable.

    The biomolecular assessment will be centralized to the reference centers (to be defined).

  3. Measurable or evaluable disease
  4. Surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or easier, or likely more feasible, after cytoreduction, and/or metastatic disease. Debulking surgery before enrolment is allowed. In this case, enrolment should occur at least one month after surgery
  5. Performance status 0, 1, 2 or 3 (ECOG) (see § 8.1).
  6. Adequate end organ function, defined as the following: total bilirubin <1.5 x ULN, SGOT and SGPT <2.5 x UNL (or <5 x ULN if hepatic metastases are present), creatinine <1.5 x ULN.
  7. Adequate bone marrow function, defined as the following: ANC >1.5 x 10^9/L, platelets >100 x 10^9/L, Hb >9 g/dL. Blood transfusions are allowed to reach the baseline requested Hb level.
  8. Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  9. Written, voluntary, informed consent.

Exclusion Criteria:

  1. Previous treatment with any other investigational or not investigational agents within 28 days of first day of study drug dosing.
  2. Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse.
  3. Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., congestive heart failure, myocardial infarction within 6 months of study)
  4. Severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
  5. Known brain metastasis.
  6. Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
  7. Known diagnosis of human immunodeficiency virus (HIV) infection.
  8. Previous radiotherapy to >=25 % of the bone marrow.
  9. Major surgery within 2 weeks prior to study entry.
  10. Expected non-compliance to medical regimens.
Sexes Eligible for Study: All
Child, Adult, Older Adult
Contact information is only displayed when the study is recruiting subjects
Italy,   Switzerland
Not Provided
Not Provided
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP